3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
9
Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Non-Small-Cell Lung
7
Triple Negative Breast Neoplasms
6
Pancreatic Neoplasms
6
Colorectal Neoplasms
5
Lymphoma
4
Liver Neoplasms
4
Lung Neoplasms
3
Kidney Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Nasopharyngeal Carcinoma
2
Multiple Myeloma
2
Mesothelioma
2
Locally Advanced Rectal Cancer
2
Hematologic Diseases
2
Esophageal Squamous Cell Carcinoma
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Adenocarcinoma
2
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Interventions
Gemcitabine
23
Capecitabine
17
Cisplatin
11
Oxaliplatin
10
Fluorouracil
9
Leucovorin
8
Irinotecan
7
Erlotinib Hydrochloride
6
pembrolizumab
5
Radiotherapy
5
Sorafenib
4
Interleukin-12 Subunit p35
3
Cholangiopancreatography, Endoscopic Retrograde
3
Carboplatin
3
regorafenib
2
dehydroftorafur
2
Watchful Waiting
2
Trastuzumab
2
Pancreaticoduodenectomy
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Long-Term Synaptic Depression
2
Lapatinib
2
Filgrastim
2
Epirubicin
2
Drug Therapy
2
Dihematoporphyrin Ether
2
Chemotherapy, Adjuvant
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
tremelimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Bile Duct Neoplasms
×
spartalizumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts